185 related articles for article (PubMed ID: 12763937)
1. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
Amrolia PJ; Muccioli-Casadei G; Yvon E; Huls H; Sili U; Wieder ED; Bollard C; Michalek J; Ghetie V; Heslop HE; Molldrem JJ; Rooney CM; Schlinder J; Vitetta E; Brenner MK
Blood; 2003 Sep; 102(6):2292-9. PubMed ID: 12763937
[TBL] [Abstract][Full Text] [Related]
2. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.
Montagna D; Yvon E; Calcaterra V; Comoli P; Locatelli F; Maccario R; Fisher A; Cavazzana-Calvo M
Blood; 1999 May; 93(10):3550-7. PubMed ID: 10233908
[TBL] [Abstract][Full Text] [Related]
3. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
Davies JK; Koh MB; Lowdell MW
Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
[TBL] [Abstract][Full Text] [Related]
4. Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation.
Amrolia PJ; Mucioli-Casadei G; Huls H; Heslop HE; Schindler J; Veys P; Vitetta ES; Brenner MK
Cytotherapy; 2005; 7(2):116-25. PubMed ID: 16047416
[TBL] [Abstract][Full Text] [Related]
5. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
Hartwig UF; Nonn M; Khan S; Meyer RG; Huber C; Herr W
Bone Marrow Transplant; 2006 Feb; 37(3):297-305. PubMed ID: 16327814
[TBL] [Abstract][Full Text] [Related]
6. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
[TBL] [Abstract][Full Text] [Related]
7. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
Wehler TC; Nonn M; Brandt B; Britten CM; Gröne M; Todorova M; Link I; Khan SA; Meyer RG; Huber C; Hartwig UF; Herr W
Blood; 2007 Jan; 109(1):365-73. PubMed ID: 16931626
[TBL] [Abstract][Full Text] [Related]
8. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
Hartwig UF; Nonn M; Khan S; Link I; Huber C; Herr W
Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
[TBL] [Abstract][Full Text] [Related]
9. Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use.
Albon SJ; Mancao C; Gilmour K; White G; Ricciardelli I; Brewin J; Lugthart G; Wallace R; Amrolia PJ
Cytotherapy; 2013 Jan; 15(1):109-21. PubMed ID: 23260091
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.
Samarasinghe S; Mancao C; Pule M; Nawroly N; Karlsson H; Brewin J; Openshaw P; Gaspar HB; Veys P; Amrolia PJ
Blood; 2010 Jan; 115(2):396-407. PubMed ID: 19890093
[TBL] [Abstract][Full Text] [Related]
11. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.
Michálek J; Collins RH; Vitetta ES
Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844
[TBL] [Abstract][Full Text] [Related]
12. CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.
Ge X; Brown J; Sykes M; Boussiotis VA
Biol Blood Marrow Transplant; 2008 May; 14(5):518-30. PubMed ID: 18410894
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.
Amrolia PJ; Muccioli-Casadei G; Huls H; Adams S; Durett A; Gee A; Yvon E; Weiss H; Cobbold M; Gaspar HB; Rooney C; Kuehnle I; Ghetie V; Schindler J; Krance R; Heslop HE; Veys P; Vitetta E; Brenner MK
Blood; 2006 Sep; 108(6):1797-808. PubMed ID: 16741253
[TBL] [Abstract][Full Text] [Related]
14. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions.
Mavroudis DA; Dermime S; Molldrem J; Jiang YZ; Raptis A; van Rhee F; Hensel N; Fellowes V; Eliopoulos G; Barrett AJ
Br J Haematol; 1998 Jun; 101(3):565-70. PubMed ID: 9633903
[TBL] [Abstract][Full Text] [Related]
15. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
16. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
17. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions.
Datta AR; Barrett AJ; Jiang YZ; Guimarães A; Mavroudis DA; van Rhee F; Gordon AA; Madrigal A
Bone Marrow Transplant; 1994 Oct; 14(4):517-24. PubMed ID: 7858526
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination.
Cavazzana-Calvo M; Stephan JL; Sarnacki S; Chevret S; Fromont C; de Coene C; Le Deist F; Guy-Grand D; Fischer A
Blood; 1994 Jan; 83(1):288-98. PubMed ID: 8274744
[TBL] [Abstract][Full Text] [Related]
19. Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy.
Bachar-Lustig E; Lask A; Eidelstein Y; Or-Geva N; Gidron-Budovsky R; Nathansohn-Levy B; Eyrich M; Liu WH; Dang G; Miranda KC; Ramirez A; Kaur I; Rezvani K; Shpall E; Champlin RE; Nagler A; Shimoni A; Barnees-Kagan S; Reisner Y
Transplant Cell Ther; 2024 Jan; 30(1):71.e1-71.e13. PubMed ID: 37890590
[TBL] [Abstract][Full Text] [Related]
20. Depletion of Alloreactive T-Cells by Anti-CD137-Saporin Immunotoxin.
Lee SC; Seo KW; Kim HJ; Kang SW; Choi HJ; Kim A; Kwon BS; Cho HR; Kwon B
Cell Transplant; 2015; 24(6):1167-81. PubMed ID: 24594433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
